Cholesterol drug results 'reassuring for patients'

17 August 2017

Phase III results published in the New England Journal of Medicine (NEJM) have shown that lowering LDL cholesterol levels with Repatha (evolocumab) does not impair cognition.

The cognitive function trial was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study, FOURIER. This trial showed that Repatha, a human monoclonal antibody from US biotech Amgen (Nasdaq: AMGN) that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), was non-inferior to placebo.

"These findings add to the body of evidence supporting the safety of LDL-lowering with Repatha in patients with established cardiovascular disease who need more than statin therapy alone"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK